Busulfan, Melphalan, and Bortezomib versus High-Dose Melphalan as a Conditioning Regimen for Autologous Hematopoietic Stem Cell Transplantation in Multiple Myeloma

High-dose melphalan 200 mg/m(2) (MEL 200) is the standard of care as a conditioning regimen for autologous hematopoietic stem cell transplantation (AHSCT) for multiple myeloma (MM). We compared a novel conditioning combination incorporating busulfan, melphalan, and bortezomib (BUMELVEL) versus stand...

Popoln opis

Shranjeno v:
Bibliografske podrobnosti
izdano v:Biol Blood Marrow Transplant
Main Authors: Rodriguez, Tulio E., Hari, Parameswaran, Stiff, Patrick J., Smith, Scott E., Sterrenberg, Danielle, Vesole, David H.
Format: Artigo
Jezik:Inglês
Izdano: 2016
Teme:
Article
Online dostop:https://ncbi.nlm.nih.gov/pmc/articles/PMC5075527/
https://ncbi.nlm.nih.gov/pubmed/27164062
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.bbmt.2016.03.021
Oznake: Označite
Brez oznak, prvi označite!

Podobne knjige/članki